RxDoctor Payments Data

Kyle White

Family · Sierra Vista, AZNPI 1497293328

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,277 of the $15,030 with a category attached, or 68.4%. 36 manufacturers reported payments, led by Abbott at 30.3% of the total. Reporting peaked in 2024 at $4,456 and has fallen 67.8% since, to $1,435 in 2025. Among family clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,030in general payments, 2019–2025

Across 387 payments — averaging $38.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Medtronic$4K
  • Pacira Pharmaceuticals Incorporated$1K
  • AbbVie$1K
  • Collegium Pharmaceutical, Inc.$772
  • Biodelivery Sciences International, Inc.$673
  • plus $3K from 30 others

What the payments were for

  • Speaking & faculty fees$6004%
  • Travel & lodging$4,05427%
  • Food & beverage$10,27768%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,030 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate35$21,413
BelbucaBuprenorphine Hcl24$16,198
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen644$15,336
Pregabalin357$13,749
Gabapentin581$9,196
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen319$8,843
Buprenorphine53$8,318
Oxycodone Hcl371$7,884
SymproicNaldemedine Tosylate11$5,153
MovantikNaloxegol Oxalate12$5,093
Duloxetine Hcl189$4,979
ButransBuprenorphine11$3,756
Morphine Sulfate ErMorphine Sulfate107$2,260
Lidocaine17$2,122
Baclofen99$2,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$772$37,61159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Sierra Vista

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →